Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Midatech receives £450,000 payment as part of vaccines deal

"I am pleased to see progress being made in the adaptation of our gold nanoparticle technology for use in vaccines for infectious disease,” said chief executive Jim Phillips.
Midatech receives £450,000 payment as part of vaccines deal
The company has received a financial boost from its collaboration.

Midatech Pharma Plc (LOM:MTPH, NASDAQ:MTP) said it had received £450,000 under the terms of its contract with Emergex Vaccines.

The latter is using the former’s gold nanoparticle platform to develop of vaccines for flu, meningitis, bacterial pneumonia, Ebola and a number of other infectious diseases. This is the first deployment of the technology in this setting.

"I am pleased to see progress being made in the adaptation of our gold nanoparticle technology for use in vaccines for infectious disease,” said chief executive Jim Phillips.

 “[This] perfectly complements our type 1 diabetes collaboration in antigen specific immunotherapy, and our early-stage internal programs which address auto-immune disease and immuno-oncology."

View full MTPH profile View Profile

Midatech Pharma Plc Timeline

Related Articles

Cholesterol gauge
July 25 2017
The assessment of Lojuxta, also known as lomitapide, followed the progress of patients with Homozygous Familial Hypercholesterolaemia
GW_Pharma.png
June 07 2017
Midatech has three lead R&D programmes: a carcinoid syndrome treatment; a liver cancer drug; and a brain cancer therapy

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use